

# Clinical and molecular characteristics of mucosal signet-ring cell carcinoma in *Helicobacter pylori*-uninfected stomach

**Mariko Kiso**

Hiroshima University Hospital

**Yuji Urabe** (✉ [beyan13@hiroshima-u.ac.jp](mailto:beyan13@hiroshima-u.ac.jp))

Hiroshima University Hospital <https://orcid.org/0000-0003-0942-1541>

**Masanori Ito**

Hiroshima University Hospital

**Kazuhiko Masuda**

Miyoshi Central Hospital

**Tomoyuki Boda**

Hiroshima University Hospital

**Takahiro Kotachi**

Hiroshima University Hospital

**Kosaku Hata**

Chugoku Rosai Hospital

**Naoki Yorita**

Hiroshima University Hospital

**Naoko Nagasaki**

Hiroshima University Hospital

**Madina Abduwali**

Hiroshima University Hospital

**Yuich Hiyama**

Hiroshima University Hospital

**Shiro Oka**

Hiroshima University Hospital

**Shinji Tanaka**

Hiroshima University Hospital

**Kazuaki Chayama**

Hiroshima University Hospital

---

## Research article

**Keywords:** *Helicobacter pylori*, uninfected, signet ring cell carcinoma, next generation sequence, smoking

**Posted Date:** May 8th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-26608/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published on July 29th, 2020. See the published version at <https://doi.org/10.1186/s12876-020-01387-9>.

# Abstract

**Background:** Gastric cancer develops even in *Helicobacter pylori*-uninfected patients and its typical histological feature is signet ring cell carcinoma (SRCC) within the mucosal layer. However, the biological characteristics of SRCC remain unclear. We aimed to clarify the pathological and genetic features of SRCC in *Helicobacter pylori*-uninfected patients.

**Methods:** Seventeen *Helicobacter pylori*-uninfected patients with mucosal SRCCs were enrolled and their clinicopathological characteristics were compared with those of *Helicobacter pylori*-infected patients with mucosal SRCCs. Seven SRCCs without *Helicobacter pylori* infection, including two invasive SRCCs, and seven *Helicobacter pylori*-positive SRCCs were subjected to a genetic analysis using next-generation sequencing.

**Results:** *Helicobacter pylori*-uninfected patients with mucosal SRCCs revealed male dominance and a significantly higher prevalence of smokers among them as compared with the *Helicobacter pylori*-infected patients with SRCC. A *CDH1* mutation (frame shift indel) was detected in one *Helicobacter pylori*-uninfected cancer not only in the mucosal SRCC but also in the invasive portion. A *TP53* mutation was detected in one SRCC without *Helicobacter pylori* infection. In the control group, *ARID1A* and *TP53* mutations were detected in one SRCC each. The C to A mutation, which is a characteristic smoking-induced mutation, was not found in any of the samples.

**Conclusions:** Some SRCCs in *Helicobacter pylori*-uninfected patients may have a malignant potential similar to that of SRCCs in *Helicobacter pylori*-infected patients. Smoking is not a main carcinogenic factor for the development of SRCCs.

## Background

It is well recognized that *Helicobacter pylori* (*H. pylori*) infection is the main cause of gastric cancer development [1]. In Japan, we previously reported that over 99% of patients with gastric cancer had *H. pylori* infection [2], and another study reported a similar result [3]. However, gastric cancer may develop even in *H. pylori*-uninfected patients and its typical histological feature is signet ring cell carcinoma (SRCC) within the mucosal layer [4]. Endoscopically, SRCCs can be easily recognized as whitish depressed or flat lesions, and their prevalence and clinical importance have recently been increasing [5].

Previous reports have suggested that SRCCs in *H. pylori*-uninfected patients show a lower proliferative activity, few extensive spread, and slower progression, compared with SRCCs with *H. pylori*-infected patients [6]. The features of SRCCs in *H. pylori*-uninfected patients resemble those in patients with hereditary diffuse gastric cancer (HDGC), which is caused by a germline mutation of *CDH1* [7]. In patients with HDGC, a large number of SRCCs can be detected; however, most of them show little tendency to invade into the submucosal layer. Therefore, it is controversial whether SRCCs in *H. pylori*-uninfected patients can invade into the submucosal layer. In addition, the pathogenesis of SRCCs in *H. pylori*-uninfected patients remains uncertain. Recently, Horiuchi *et al.* reported the implication of smoking in the disease pathogenesis of these patients, noting that their findings should be verified by other studies [8].

In the present study, we compared the clinical features of SRCCs between patients with and without *H. pylori* infection. Moreover, we investigated the genomic characteristics of these lesions to identify their biological characteristics and assess whether smoking may be involved in their pathogenesis.

## Methods

### Patients

We enrolled 19 consecutive patients with SRCC (17 with mucosal cancer and 2 with invasive cancer) without *H. pylori* infection who were diagnosed in Hiroshima University Hospital from 1998 to 2017. All the patients received endoscopic or surgical resection. The entire tumor was cut into parallel 2–4 mm-thick sections for investigation. Histological evaluation was performed according to the Japanese gastric cancer treatment guidelines [9]. Clinicopathological data was retrospectively reviewed from clinical records. The definition of *H. pylori*-negative subjects was judged by our criteria as described in a previous publication [2].

A total of 34 patients with *H. pylori*-positive SRCC diagnosed in the same period were enrolled as controls. This retrospective study was approved by the institutional review board and the ethics committees of Hiroshima University (No. E-1237) and was performed in accordance with the Helsinki Declaration and its later amendments.

### Tissue capture and DNA extraction

In the experiments with next-generation sequencing, we randomly selected seven patients who were habitual smokers among both the *H. pylori*-negative and -positive SRCCs. Two invasive SRCCs (Case 5 and 6) were included in the *H. pylori*-uninfected group. In these two cases, the tumors were composed of a mucosal SRCC and a poorly differentiated adenocarcinoma (PDA) component in the deeper portion.

Pathologic tumor tissues were dissected from ten 10- $\mu$ m-thick slides made from formalin-fixed paraffin embedded (FFPE) specimens, which were deparaffinized, stained, and dehydrated using the Arcturus® Paradise® PLUS Reagent System (Thermo Fisher Scientific, Waltham, MA, USA). Dissections were performed using a laser capture microdissection system (LMD 6500, Leica, Wetzlar, Germany), in accordance with the pathogenesis diagnosis. The DNA was extracted from these tissues using the GeneRead DNA FFPE kit (Qiagen, Valencia, CA, USA), and concentrations were determined using a Qubit® 1.0 fluorometer (Life Technologies, Carlsbad, CA, NY, USA). The quantity and quality of the FFPE-derived DNA samples were checked by calculating the normalized DNA integrity scores ( $\Delta\Delta Cq$ ) via quantitative polymerase chain reaction (PCR) analysis using the Agilent NGS FFPE QC kit (Agilent, Santa Clara, CA, USA).

### Target enrichment and next-generation sequencing

DNA extracted from tumors was fragmented into 150–200 bp portions by sonication using an S2 sonicator (6 min, 10% duty, intensity = 5, 200 cycles/burst; Covaris, Woburn, MA, USA) and used for library construction according to the manufacturer's instructions. In all cases, 10 ng of DNA was prepared for sequencing. The exons of ten oncogenes (*CDH1*, *TP53*, *ARID1A*, *KRAS*, *PIK3CA*, *ERBB3*, *FBXW7*, *TGFBR1*, *RHOA*, and *MAK2K1*) were enriched using the SureSelectXT HS Custom panel (Agilent). The resulting pooled libraries were quality control-checked via the High Sensitivity D1000 ScreenTape system using the 2200 TapeStation instrument (Agilent). Sequencing was performed with paired-end reads via the HiSeq 2500 platform (Illumina, San Diego, CA, USA).

### Variant detection

Sequencing reads were aligned to the hg19/GRCh37 reference sequence and analyzed using SureCall 4.0.1 (Agilent). PCR duplicates were removed and low-frequency mutations in template DNA molecules were detected using the molecular barcode system [10]. To identify variants in tumor samples, single sample analysis in SureCall 4.0.1 was used. The called variants were considered germline mutations if they were found in the dbSNP 137 or

TogoVar (<https://togovar.biosciencedbc.jp>) databases. The remaining mutations in cancerous tissues were considered to be candidate cancer-specific mutations. To reduce the false positive rate, we set the cutoff values for somatic mutation in cancerous tissues as follows: variant score > 0.3; minimum quality for base > 30; variant call quality > 100; allele frequency > 0.1; and number of reads supporting the variant allele > 3 (Supporting file 1).

## Statistical analysis

All clinicopathological features were analyzed using the Chi-square test or Fisher's exact test to compare categorical data and Student's *t* test or Wilcoxon rank-sum test to compare continuous data. A *p*-value of < 0.05 was considered significant. All statistical analyses were performed using JMP® software (SAS International, Cary, NC, USA).

## Results

### *Comparison of clinical features between H. pylori-uninfected and -infected signet ring cell carcinomas*

First, we compared the clinicopathological features between 17 *H. pylori*-uninfected and -infected patients with SRCCs located within the mucosal layer. As shown in Table 1, the *H. pylori*-uninfected patients with mucosal SRCCs revealed male dominance and a slightly younger age than the *H. pylori*-infected patients. The SRCCs in the *H. pylori*-uninfected patients tended to be located in the lower third of the stomach and its tumor size were significantly smaller than those in the *H. pylori*-infected patients. Although no difference was detected in blood type, family history of gastric cancer, or alcohol consumption, the prevalence of smokers was significantly higher among the *H. pylori*-uninfected patients (*p* = 0.02), although the Brinkman index was not different between the two groups.

### *Next-generation sequencing of SRCC tissue samples*

DNA analysis by next-generation sequencing was performed in 16 samples from 14 patients (seven patients from each group) as shown in Table 2. We examined 10 diffuse-type gastric cancer associated genes (*CDH1*, *TP53*, *ARID1A*, *KRAS*, *PIK3CA*, *ERBB3*, *FBXW7*, *TGFBR1*, *RHOA*, and *MAK2K1*) referring to previous paper [11]. In addition, two DNA samples (one from an SRCC within the mucosal layer and one from a deeper PDA lesion) were extracted from two cases with invasive SRCC without *H. pylori* infection. In the control group, seven samples were collected from only mucosal SRCC with *H. pylori* infection. Therefore, in total, nine and seven DNA samples were extracted from the *H. pylori*-uninfected and -infected patients, respectively.

Finally, a single gene mutation was detected in each of five samples (Table 3, Figure 1). A *CDH1* mutation (frame shift indel) was detected only in one *H. pylori*-uninfected cancer lesion (case 6) (Figure 1). This mutation was found not only in the mucosal SRCC but also in the invasive PDA of that patient (Figure 2,3). A *TP53* mutation was detected in one SRCC without *H. pylori* infection (case 4). In the *H. pylori*-infected control group, mutations in *ARID1A* (case 11) and *TP53* (case 12) were detected in SRCCs (Figure 1). No mutation in *CDH1* was found in the control group. Furthermore, the C to A mutation, which is a characteristic smoking-induced mutation, was not found in any of the samples. On the other hand, we did not find somatic mutation in 7 genes (*KRAS*, *PIK3CA*, *ERBB3*, *FBXW7*, *TGFBR1*, *RHOA*, and *MAK2K1*) which associated somatic genomic alterations associated with the unique characteristics of sporadic diffuse gastric cancers [11]. (Figure 1)

## Discussion

In the present study, we examined the clinical and genetic characteristics of SRCCs in patients without *H. pylori* infection. SRCCs in patients without *H. pylori* infection showed different features compared with those in patients

with *H. pylori* infection. Clinically, the *H. pylori*-uninfected patients with mucosal SRCCs showed male dominance and the tumor tissue tended to be located in the lower third of the stomach. These observations imply that *H. pylori*-uninfected SRCCs have distinct biological characteristics and probably have a different carcinogenetic pathway as compared with *H. pylori*-infected SRCCs.

Particular focus should be placed on the genetic alterations detected in SRCCs without *H. pylori* infection. Generally, diffuse-type cancers including SRCC are classified into the “genomically stable group” according to the four-subtype classification [12]. Under these conditions, *CDH1* have frequently been detected in SRCCs in patients with HDGC [13]. Moreover, E-cadherin, which is coded by *CDH1* gene, regulates signaling pathways leads to increase in cell proliferation, decrease in cell apoptosis followed by gastric cancer development [14]. However, in our study, the prevalence of mutations in *CDH1* was extremely low in SRCCs without *H. pylori* infection. This suggests that the carcinogenic pathway of SRCCs without *H. pylori* infection differs from that of SRCCs in patients with HDGC. The SRCC lesions found in *H. pylori*-uninfected patients seem to reflect not only a defect in cell-cell adhesion but also other neoplastic alterations.

Mutations in *TP53*, which are known as a representative driver mutation in gastric cancer carcinogenesis, were detected in SRCCs without *H. pylori* infection as well as those with *H. pylori* infection. This also strongly suggests that SRCCs in *H. pylori*-uninfected patients may be true neoplastic lesions. Previous reports have demonstrated that SRCC tissue gains an invasive ability after the mutation of *TP53* followed by conversion to PDA [15]. Accordingly, at least in a part of *H. pylori*-uninfected SRCC is a true neoplasm, and clinical features of SRCC without *H. pylori* infection may be different from that in HDGC. In the present study, we demonstrated the presence of similar genetic alterations between mucosal SRCC and invasive PDA in a *H. pylori*-uninfected patient, suggesting the progression of SRCC to invasive PDA. Indeed, we have diagnosed two cases with invasive SRCC without *H. pylori* infection (paper under submission). SRCC without *H. pylori* infection may have a malignant potential to invade into the submucosal layer and should be treated as a diffuse-type gastric cancer as described in the guidelines for treatment [16].

Notably, it should be emphasized that the prevalence of smokers was higher among the *H. pylori*-uninfected patients with SRCCs than among the *H. pylori*-infected patients. This finding is compatible with the previous report by Horiuchi et al. [8]. However, in our study concerning the genetic alterations in SRCC tissue samples, we could not find any C to A mutations, which are recognized as smoking-induced alterations, despite including samples from some heavy smokers in our analysis [17, 18]. Smoking may be a confounding factor as to the pathogenesis of SRCCs without *H. pylori* infection.

In addition to genetic mutations, gastric carcinogenesis may also be influenced by epigenomic alterations including gene methylation. Epstein–Barr virus (EB virus) infection, which induces several epigenetic alterations in host genes, may be another carcinogenetic factor besides *H. pylori* infection [19]. However, it is supposed that *H. pylori* infection is essential for EB virus-induced carcinogenesis [20]. The pathogenesis of SRCCs without *H. pylori* infection remains unclear and should be clarified in future research.

This study has several limitations. The first limitation is the limited number of patients. To accurately evaluate the prevalence of any given genetic mutation, a large number of cases should be examined. In addition, we examined only ten genes in our cancer panel and we could not cover their complete exon sequences. In clinical practice, SRCCs without *H. pylori* infection are diagnosed when the lesions measure about 10 mm in diameter; therefore, it is difficult to extract high quality DNA from SRCC tissue. The second limitation is that DNA samples from control

lymphocytes were not analyzed. Therefore, we excluded disease-specific germline mutations and Japanese healthy germline mutations when searching the dbSNP 137 and TogoVar databases.

## Conclusions

We have demonstrated the clinical features of patients with SRCCs without *H. pylori* infection and described some genetic alterations detected in these lesions. Our findings indicate that SRCCs without *H. pylori* should be treated as having a malignant potential similar to that for SRCCs occurring in the presence of *H. pylori* infection.

## Declarations

### Availability of data and materials

The datasets used and analyzed during the current study will be available from the corresponding author on reasonable request.

### Acknowledgements

Quality check by TapeStation (Agilent, Santa Clara, CA, USA) was supported by the Program of the network-type Joint Usaga/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University. Next-generation sequencing was carried out at the Analysis Center of Life Science, Hiroshima University.

### Finding

This study was funded by the Tsuchiya Memorial Medical Foundation (grant number 33-3). No additional external funding was received for this study.

### Author information

#### Affiliations

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.

Mariko Kiso, Naoki Yorita, Naoko Nagasaki, Madina Abduwali, Yuich Hiyama,

Shiro Oka, Kazuaki Chayama

Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.

Yuji Urabe

Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.

Masanori Ito

Department of Gastroenterology, Miyoshi Central Hospital, 10531 Higashisakeyamachi, Miyoshi, Hiroshima 728-8502 Japan.

Kazuhiko Masuda

Department of Endoscopy, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.

Tomoyuki Bodaie, Takahiro Kotachie, Shinji Tanaka

Department of Gastroenterology, Chugoku Rosai Hospital, 1-5-1 Hirotagaya, Kure, 737-0193 Japan.

Kosaku Hata

### **Contributions**

Conception and design of the study; Y.U., M.I., Analysis and interpretation of data; K.M., Y.U., K.M., Collection and assembly of data; K.M., T.B., T.K., K.H., N.Y., N.N., M.A., Y.H., S.O., S.T., Drafting of the article; K.M., Y.U., M.I., Critical revision of the article for important intellectual content; K.M., Final approval of the article; K.C.

### **Corresponding author**

Correspondence to Yuji Urabe.

### **Ethics declarations**

### **Ethics approval and consent to participate**

All procedures were completed in accordance with the Declaration of Helsinki of 1964 and later versions. The Ethics Committee of Hiroshima University Hospital approved our study (E-1237). Informed consent was obtained from all patients by opt-out.

### **Consent for publication**

Not applicable.

### **Competing interests**

The authors declare that they have no competing interests.

### **Additional information**

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## **Abbreviations**

**SRCC:** signet ring cell carcinoma

***H.pylori.*** *Helicobacter pylori*

**HDGC:** hereditary diffuse gastric cancer

**PDA:** poorly differentiated adenocarcinoma

**FFPE:** formalin-fixed paraffin embedded

**EB virus:** Epstein–Barr virus

## References

1. IARC Working Group Reports Volume 8. *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer.
2. Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of *Helicobacter pylori*-negative gastric cancer among Japanese. *Helicobacter* 2011;16:415-9.
3. Ono S, Kato M, Suzuki M, Ishigaki S, Takahashi M, Haneda M, et al. Frequency of *Helicobacter pylori*-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. *Digestion* 2012;86:59-65.
4. Kiso M, Yoshihara M, Ito M, Inoue K, Kato K, Nakajima S, et al. Characteristics of gastric cancer in negative test of serum anti-*Helicobacter pylori* antibody and pepsinogen test: a multicenter study. *Gastric Cancer*. 2017;20:764-71.
5. Yamamoto Y, Fujisaki J, Omae M, Hirasawa T, Igarashi M. *Helicobacter pylori*-negative gastric cancer: characteristics and endoscopic findings. *Dig Endosc*. 2015;27:551-61.
6. Horiuchi Y, Fujisaki J, Yamamoto N, Shimizu T, Miyamoto Y, Tomida H, et al. Biological behavior of the intramucosal *Helicobacter pylori*-negative undifferentiated-type early gastric cancer: comparison with *Helicobacter pylori*-positive early gastric cancer. *Gastric Cancer*. 2016;19:160-5.
7. Sugimoto S, Komatsu H, Morohoshi Y, Kanai T. Recognition of and recent issues in hereditary diffuse gastric cancer. *J Gastroenterol*. 2015;50:831-43.
8. Horiuchi Y, Fujisaki J, Ishizuka N, Omae M, Ishiyama A, Yoshio T, et al. Study on clinical factors involved in *Helicobacter pylori*-uninfected, undifferentiated-type early gastric cancer. *Digestion*. 2017;96:213-9.
9. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017;20:1-19.
10. Peng Q, Vijaya Satya R, Lewis M *BMC Genomics*. 2015; 16: 589, <https://www.agilent.com/cs/library/brochures/5991-8014EN.pdf>.
11. Cho SY, Park JW, Liu Y, Park YS, Kim JH, Yang H, et al. Sporadic early-onset diffuse gastric cancers have high frequency of somatic *CDH1* alterations, but low frequency of somatic *RHOA* mutations compared with late-onset cancers. *Gastroenterology*. 2017;153:536-549.
12. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014;513:202-9.
13. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. *JAMA Oncol*. 2015;1:23-32.
14. Liu X, Chu KM. E-cadherin and gastric cancer: cause, consequence, and applications. *Biomed Res Int*. 2014;2014:637308.

15. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. *Gut*.2012;61:344-53.
16. Ono H, Yao K, Fujishiro M, Oda I, Nimura S, Yahagi N, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. *Dig Endosc*. 2016;28:3-15.
17. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. *J Natl Cancer Inst*. 2000;92:803-11.
18. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanière P, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. *Cancer Res*. 2005; 65:5076-83.
19. Saju P, Murata-Kamiya N, Hayashi T, Senda Y, Nagase L, Noda S, et al. Host SHP1 phosphatase antagonizes *Helicobacter pylori* CagA and can be downregulated by Epstein-Barr virus. *Nat Microbiol*. 2016;1:16026.
20. Nishikawa J, Iizasa H, Yoshiyama H, Nakamura M, Saito M, Sasaki S, et al. The role of epigenetic regulation in Epstein-Barrvirus-associated gastric cancer. *Int J Mol Sci*. 2017;18.f

## Tables

Table 1. Comparison of *Helicobacter pylori*-uninfected and -infected mucosal signet ring cell carcinoma

	HpU-SRCC (n = 17)	HpP-SRCC (n = 34)	p-value
Male/Female	15/2	14/20	0.004
Age	53.2 ± 11.4	58.2 ± 13.2	n.s.
Location			
Upper third	2 (11.8%)	0	n.s.
Middle third	4 (23.5%)	24 (70.6%)	
Lower third	11 (64.7%)	10 (29.4%)	
Size	9.1 ± 5.3	16.0 ± 11.7	0.03
Blood type (A/B/O/AB)	8/1/5/3	16/4/9/5	n.s.
Family history* of gastric cancer	6/13 (46%)	7/23 (30%)	n.s.
Alcohol	10/17 (59%)	16/26 (62%)	n.s.
Smoking	11/17 (65%)	6/26 (23%)	0.02
Brinkman Index	563.6	526.7	

HpU-SRCC: *Helicobacter pylori*-uninfected signet-ring cell carcinoma, HpP-SRCC: *Helicobacter pylori* positive (infected) signet-ring cell carcinoma, n.s.: not significant

\* Family History: relative within the 3-degree relationship

With drinking history, drink alcohol 21.6 g/day or more and drink more than 3 days a week as a drinker. And with smoking history, defined including smoking in present and in the past.

Table 2. Clinical characteristic of signet ring cell carcinoma subjected to gene analysis

ori on	Age	Sex	Position	Size (mm)	Macroscopic type	Histology	Depth	Period*
ve	42	M	antrum	8	0-IIc	Sig	M	8y
ve	65	M	angular region	5	0-IIc	Sig	M	7y
ve	41	M	antrum	20	0-IIc	Sig	M	6y
ve	40	M	antrum	5	0-IIc	Sig	M	3y
ve	64	M	upper body	20	SMT	Por2>Sig	SS	3y
ve	36	M	fornix	30	0-IIc	Por1>Sig	SE	17y
ve	49	M	antrum	10	0-IIc	Sig	M	3y
ve	50	F	middle body	5	0-IIc	Sig	M	7y
ve	52	F	angular region	15	0-IIc	Sig	M	8y
ve	55	F	angular region	20	0-IIc	Sig	M	8y
ve	57	F	antrum	10	0-IIc	Sig	M	7y
ve	40	M	angular region	8	0-IIc	Sig	M	7y
ve	46	M	antrum	10	0-IIc	Sig	M	7y
ve	68	M	angular region	25	0-IIc	Sig	M	7y

Sig: signet ring cell carcinoma, por1: Poorly differentiated adenocarcinoma solid type, por2: Poorly differentiated adenocarcinoma non-solid type, M: mucosa, SS: subserosa, SE: serosa

\*The period among paraffin embedding (years)

Table 3. Gene mutation detected in 16 samples

Category	Impact Gene	Chrom	Position	Ref Allele	Alt Allele	Allele Frequency	Read depth	Function Class	Codon	AA
	TP53	17	7579542	C	G	0.39	251	MISSENSE	Gat/Cat	D10H
	CDH1	16	68853327	TG	T	0.51	49			
	CDH1	16	68853327	TG	T	0.57	69			
	ARID1A	1	27106333	G	A	0.571	105	MISSENSE	Gtc/Act	V1765I
	TP53	17	7579705	C	T	0.48	123	MISSENSE	Gtt/Att	V31I

Sig: signet ring cell carcinoma, por1: Poorly differentiated adenocarcinoma solid type

## Figures

Figure 1. **【mutation profiling】**





Figure 1

Mutational landscapes of Seven SRCCs without *Helicobacter pylori* infection, and seven *H. pylori*-positive SRCCs. Gastric signet ring cell carcinoma (SRCCs) tissues, paired non-cancerous tissues, from Seven SRCCs without *Helicobacter pylori* (*H. pylori*) infection, and seven *H. pylori*-positive SRCCs were subjected to the targeted panel for 10 genes. The Upper bar-graph shows the number of somatic mutations per sample. The Lower panel shows the type of mutation of each gene. Genes reported SRCC-associated genes in previous paper. First line shows *H. pylori*-infect, second line shows smoking status, and from 3th to 12th line shows the type of mutation of each gene. Blue panels shows *H. pylori*-infected cases, brown panels shows present or current smoker, light-brown panels shows non-smoker, red panels shows frameshift indels or nonsense mutations, and yellow panels shows missence mutations.

**Figure 2.**



**Figure 2**

Endoscopic features of case 6 (a 36-year-old man). Endoscopic examination showed no atrophic changes in the background mucosa [a]. A depressed lesion measuring approximately 30 mm in diameter was observed in the fornix [b].

Figure 3.




Figure 3

Histological features of case 6. A depressed lesion was found in the center of the section (a) and the low magnitude feature [red box in (a)] was demonstrated in (b). The histologic features of a higher magnitude mucosal signet ring cell carcinoma (yellow box) and a poorly differentiated adenocarcinoma in the deep invasive portion (blue box) are shown in (c) and (d), respectively (hematoxylin and eosin staining).

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supportingfile1parameter.docx](#)